CALGB 90601
A Randomized Double-Blinded Phase III Study Comparing Gemcitabine,Cisplatin, and Bevacizumab (IND #7921, NSC #704865) to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma.
Adjuvant:
CALGB 40101
Cyclophosphamide and Doxorubicin (Ca) (4 Vs 6 Cycles) Versus Paclitaxel (4 Vs 6 Cycles) as Adjuvant Therapy for Women with 0-3 Positive Axillary Lymph Nodes: A 2x2 Factorial Phase III Study
IBCSG 24-02
A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (SOFT)
CIRG (TRIO) 011/NSABP B-44-I / Roche BO20906 (BETH STUDY)
A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2 Positive Node Positive or High Risk Node Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab (US IND Sponsor: NSABP Foundation, Inc.).
ECOG PACCT -1
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial .
NSABP B-42
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer.
NSABP B-43
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy.
Metastic:
ECOG E1105
A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer.
Novartis CZOL446E2352
CZOL446E2352: A Prospective, Randomized, Double-Blind, Stratified, Multi-Center, 2-Arm Trial of the Continued Efficacy and Safety of Zometa® (every 4 weeks vs. every 12 weeks) in Patients With Documented Bone Metastases From Breast Cancer.
Genentech:TDM4370G/BO21977
A Randomized, Multicenter, Phase Iii, Open Label Study Of The Efficacy And Safety Of Trastuzumab Mcc-Dm1 Vs. Capecitabine + Lapatinib In Patients With Her2 Positive Locally Advanced Or Metastatic Breast Cancer Who Have Received Prior Trastuzumab Based Therapy.
SWOG S0518
Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC#704865) in Advanced,Poo0r Prognosis Carcinoid Patients.
Adjuvant:
ECOG E5202
A Randomized Phase III Study Comparing 5-FU Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers.
NCCTG-N0147
A Randomized Phase III Trial of Irinotecan (CPT-11) and/or Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients with Stage III Colon Cancer.
Neo-Adjuvant:
NSABP Protocol R-04
A Clinical Trial Comparing Preoperative Radiation Therapy And Capecitabine With Or Without Oxaliplatin With Preoperative Radiation Therapy And Continuous Intravenous Infusion Of 5-Fluorouracil With Or Without Oxaliplatin In The Treatment Of Patients With Operable Carcinoma Of The Rectum.
Metastatic:
CALGB C80405
A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum.
RTOG 0619
A Randomized Phase II Trial of Chemoradiotherapy versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck.
Prevention:
ECOG E5597
Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non Small Cell Lung Cancer.
Adjuvant:
ECOG E1505
A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC).
Treatment:
IIIB with effusions or IV
First Line:
Pfizer Protocol: A4021016 - 1143
Randomized, Open Label, Phase Ill Trial Of CP-751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non-Small Cell Lung Cancer (predominantly squamous).
ACORN AC01L08
A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination with Platinum-Based Chemotherapy as First Line Treatment of Patients with Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
2nd,3rd,4th Line:
Tragara Protocol No: TP2001-201
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination with Erlotinib in Non-Small Cell Lung Cancer Patients.
Treatment:
CALGB C50303
A Phase III Randomized Study of R-CHOP v. Dose-adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
ECOG E1697
Phase III Randomized Study of Four Weeks High Dose IFN-a2b in Stage T2b N0, T3a-b, T4a-b N0, and T1-4, N1a, 2a, 3 (microscopic) Melanoma
Metastic:
A. B. Science S.A Protocol AB07012
A prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, in add-on, Phase III study to compare efficacy and safety of Masitinib at 9 mg/kg/day in combination with Gemcitabine, to placebo in combination with Gemcitabine, in treatment of patients with advanced/metastatic pancreatic cancer.
Non-Metastic:
AstraZeneca: Protocol D4320C00015
A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-Metastatic Hormone Resistant Prostate Cancer.
Metastic:
AstraZeneca Protocol: D4320C00033
A Phase III, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metastatic Hormone-resistant Prostate Cancer.
ECOG E2805
A Randomized, Double Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma.
Pfizer Protocol: A6181078 – 1130
A Treatment Protocol For Patients Continuing from a Prior SU011248 Protocol
Metastic:
Sanofi-aventis Protocol EFC6521:
A multinational, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy.
EISAI Protocol FRAG-A001-401:
Dalteparin Sodium Injection (Fragmin®), Multicenter, Open Label, Single-arm, Controlled Long Term (52 Weeks) Study for Understanding Safety and Efficacy in Subjects with Malignancies and Symptomatic Venous Thromboembolism.
For more information on clinical trials please
contact research@echoassociates.org.
